#United States #San Francisco #Microbiome Science #Pendulum Therapeutics #Laxman Narasimhan

Pendulum Therapeutics Welcomes Laxman Narasimhan to Board of Directors

Pendulum Therapeutics, recognized as a cutting-edge biotechnology firm in the realm of microbiome science, has taken a significant step forward by appointing Laxman Narasimhan, the former Chief Executive Officer of Starbucks and Reckitt, to its Board of Directors. This notable addition signals not only the company's rapid expansion but also its commitment to revolutionizing human health through advanced research and development in the microbiome field.

With a sharp increase in demand for validated microbiome solutions, Pendulum is positioned to redefine health standards by harnessing the power of clinically validated probiotics. Narasimhan's extensive leadership experience in global organizations is set to enhance Pendulum's mission to elevate advanced science and make it accessible.

Narasimhan’s career is marked by his adeptness in integrating customer connection while leading major corporations. His tenure at Starbucks saw a remarkable rethinking of the brand, which resulted in a strengthened global presence and enriched customer engagements. Similarly, during his time at Reckitt, he transformed the consumer health sector, redefining the company’s purpose to cater to a healthier world.

His previous experience at PepsiCo, where he held significant roles over a decade, including Global Chief Commercial Officer, further equips him with a profound understanding of consumer brands and retail dynamics. Before joining PepsiCo, Laxman made his mark as a Senior Partner at McKinsey & Company, where he lent his expertise to Fortune 500 companies focusing on growth strategies.

“We are excited to have Laxman join our board,” said Colleen Cutcliffe, PhD, Co-Founder and CEO of Pendulum Therapeutics. “His remarkable experience with some of the world's most respected brands will not only complement our mission but actively contribute to making advanced microbiome science widely accessible.”

Narasimhan, aware of the transformative potential of microbiome science, expressed his enthusiasm: “The microbiome will be essential in how we define health moving forward. Pendulum beautifully blends science with a profound sense of purpose, and I am honored to assist in scaling these innovative solutions globally.”

Roelof Botha, Managing Partner at Sequoia Capital and a Pendulum board member, remarked on the invention’s significance. He noted that Narasimhan's decision to join during this pivotal moment further underscores the extensive opportunity Pendulum has ahead: “Pendulum is uniquely positioned to bring microbiome therapeutics to market.” Moreover, Hugh Martin, Chairman and Chief Business Officer of Pendulum, emphasized that the microbiome is on the brink of becoming a multi-trillion-dollar industry. Narasimhan's leadership would thus play a critical role in accelerating this vision.

Pendulum Therapeutics boasts a rigorous decade of research and development, establishing itself as a credible leader in microbiome science. A significant achievement includes the creation of Pendulum Glucose Control, recognized as the first and only probiotic clinically proven to lower A1C levels in patients with Type 2 diabetes. Their continued innovations underscore Pendulum's pivotal role in advancing not only gut health but also broader health implications.

The company excels in pioneering live Akkermansia muciniphila, a crucial strain that fortifies the gut lining and enhances metabolism. Presently, Pendulum has been recognized as the top Gastroenterologist Recommended Brand of Akkermansia-based probiotics, continuing to advance its innovative portfolio that seeks to unlock microbiome-related health benefits beyond traditional approaches.

Pendulum is the only probiotic endorsed by the Mayo Clinic and enjoys investment support from distinguished entities such as Sequoia Capital, Maritech Capital, True Ventures, and Khosla Ventures. This solid backing reinforces Pendulum's standing as a transformative leader within the microbiome industry.

About Pendulum Therapeutics

Pendulum Therapeutics stands at the forefront of microbiome science, combining the meticulousness of pharmaceutical development with the accessibility of dietary probiotics. Founded in 2012 and led by a team of scientists from elite institutions such as Harvard, Stanford, and UC Berkeley, Pendulum is dedicated to tackling metabolic health challenges through innovative solutions designed to reshape the future of human health.

For more information, visit www.pendulumlife.com.